Trial Profile
An Open-label, Repeated-dose, Dose Escalation Study of the Safety and Effectiveness of SANGUINATE for the Treatment of Leg Ulcers in Adult Patients With Sickle Cell Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2017
Price :
$35
*
At a glance
- Drugs PEG-haemoglobin carbon monoxide (Primary)
- Indications Leg ulcer; Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Prolong Pharmaceuticals
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
- 24 Feb 2017 Status changed to completed.
- 28 Apr 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2015.